Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 11/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065072 | 1.00 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB2CHRNA4GPR119 | |
| SCHEMBL2065062 | 0.89 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2065064 | 0.89 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2066832 | 0.88 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2066830 | 0.88 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2065459 | 0.86 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2065460 | 0.86 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2064943 | 0.85 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL2064940 | 0.85 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL1135638 | 0.85 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700639-A1 | Selective ligands for the neuronal nicotinic receptors and uses thereof | Abbvie Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8648084-B2 | Selective substituted pyrazine ligands for neuronal nicotinic receptors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8148408-B2 | Selective substituted pyridine ligands for neuronal nicotinic receptors | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | CHRNA4, CHRNB4, CHRNA2 | CHRNB4 2/4885CHRNA3 9/4885CHRNB2 4/4885 |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | CHRNA4, CHRNB4, CHRNA2 | CHRNB4 2/4885CHRNA3 7/4885CHRNB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.